The degree of tumor load reduction after therapy, which is determined by the degrees of
cytoreduction and cytogenetic response, is an important prognostic factor for patients with …

We measured using a competitive quantitative polymerase chain reaction-capillary
electrophoresis (PCR-CE)-based assay, the levels of bcr-abl transcripts in 44 patients with …

The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

We have developed a competitive polymerase chain reaction (PCR) titration assay that
estimates the number of BCR-ABL transcripts in chronic myeloid leukemia patients to …

Serial assays of qualitative (multiplex and nested) and quantitative PCR were carried out for
detecting and estimating the level of BCR-ABL transcripts in 39 CML patients following bone …

We have developed a rapid real‐time quantitative PCR method for measuring BCR‐ABL
mRNA levels in peripheral blood in chronic myeloid leukaemia (CML). The technique was …

In vitro amplification of the Bcr‐Abl cDNA has been widely used to assess for the presence
of minimal residual disease in patients with chronic myelogenous leukaemia (CML) …

In the May 1, 1999 issue of Blood, Faderl et al1 discuss the possible clinical role of
polymerase chain reaction (PCR) analysis in the surveillance of residual disease in patients …

In chronic myelogenous leukemia (CML), amplification of a segment of bcr-abl messenger
RNA (mRNA) by polymerase chain reaction (PCR) can be used to detect minimal residual …

The polymerase chain reaction (PCR) allows the detection of minimal amounts of nucleic
sequences and has been successfully used to test for the chronic myeloid leukemia-specific …